Sonavi Labs

Executive Summary

Sonavi Labs is a digital health company developing AI-powered respiratory diagnostics for home use. Its flagship product, Feelix, is a patient-driven auscultation device and platform that enables users to record lung sounds, receive AI-driven analysis, and share data with clinicians remotely. Founded in 2017 and headquartered in Baltimore, the company aims to make respiratory care more accessible, affordable, and user-friendly. Feelix addresses a critical need in chronic disease management for conditions like asthma and COPD, where early detection and continuous monitoring can prevent exacerbations and reduce healthcare costs. The platform leverages machine learning to improve diagnostic accuracy and has the potential to expand into telemedicine and remote patient monitoring markets. Sonavi Labs operates in a growing competitive landscape with players like Eko and TytoCare, but its focus on affordability and patient-driven design may differentiate it. The company has not disclosed funding or revenue details, suggesting it may be in early commercialization or seeking partnerships. Its success hinges on regulatory clearance, clinical validation, and strategic collaborations with healthcare providers. Given the increasing demand for remote diagnostics and AI in healthcare, Sonavi Labs presents a promising opportunity with moderate risk. Achieving market traction will depend on execution and securing reimbursement pathways.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance for Feelix80% success
• Q2 2026Strategic partnership with a major health system60% success
• Q3 2026Publication of clinical validation study in a peer-reviewed journal70% success